Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

Rhea-AI Summary

Inhibrx (NASDAQ: INBX) will webcast a clinical update on INBRX-106 from the randomized Phase 2 HexAgon study on May 11, 2026, 5:30 a.m. PT. The presentation will report interim results comparing INBRX-106 plus pembrolizumab versus pembrolizumab alone in first-line, PD-L1 positive (CPS ≥20) metastatic or unresectable recurrent HNSCC.

Investors can join via webinar or dial-in; the webcast will be available for 60 days and the corporate presentation will be updated on Inhibrx's website.

News Market Reaction – INBX

-5.04%

29 alerts

-5.04% Session close to close

+14.1% Peak in 7 hr 16 min

$1.97B Market Cap

0.6x Rel. Volume

In the May 11 session, INBX declined 5.04%, reflecting a notable negative market reaction. Argus tracked a peak move of +14.1% during that session. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.0% in the session following this news. A negative reaction despite this being a s...

Analysis

The stock moved -5.0% in the session following this news. A negative reaction despite this being a scheduling announcement could reflect heightened expectations around the upcoming INBRX-106 interim data. Past events, like the earnings release on Mar 19, 2026, also saw downside when broader fundamentals came into focus. The key risk is that markets may be pre-positioning around the Phase 2 HNSCC readout; actual results versus prior INBRX-106 disclosures will be critical for longer-term sentiment.

Key Figures

Webcast date: May 11, 2026 Webcast time: 5:30 a.m. PT Trial phase: Phase 2 +3 more

6 metrics

Webcast date May 11, 2026 Date of INBRX-106 HexAgon interim Phase 2 update

Webcast time 5:30 a.m. PT Start time for clinical update presentation

Trial phase Phase 2 Randomized first-line portion of HexAgon study

PD-L1 cutoff CPS ≥ 20 Eligibility for PD-L1 positive HNSCC patients

Webcast archive period 60 days Webcast replay availability on company website

Dial-in number 1-888-880-3330 Telephone access for the webcast presentation

Historical Context

5 past events · Latest: Apr 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 21	Clinical data update	Positive	+37.9%	Updated Phase 1/2 ozekibart colorectal cancer efficacy and safety results.
Apr 20	Webcast announcement	Neutral	+2.1%	Scheduled webcast to present ozekibart Phase 1/2 colorectal cancer data.
Mar 19	Earnings results	Negative	-6.1%	Reported 2025 net loss and lower R&D/G&A with 2026 milestones outlined.
Mar 02	Conference participation	Neutral	-4.1%	Planned ESMO sarcoma conference presentation on ozekibart clinical data.
Dec 16	Program update	Positive	+1.9%	Progress updates on INBRX-106 HNSCC trial and ozekibart expansion cohorts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news-driven moves have mostly aligned with the tone of announcements, with clinical updates and financial results prompting directionally consistent reactions.

Recent Company History

Over the last several months, Inhibrx has highlighted progress across ozekibart and INBRX-106. A positive colorectal cancer update on Apr 21, 2026 saw a strong +37.93% move, while a prior webcast notice on Apr 20, 2026 had a mild +2.06% reaction. Earnings on Mar 19, 2026 with a $140.1 million net loss coincided with a -6.09% move. Clinical progress updates on Dec 16, 2025 for INBRX-106 and ozekibart aligned with a modest gain, showing markets respond to substantive data.

Key Terms

phase 2, hexavalent, ox40 agonist, pembrolizumab, +4 more

8 terms

phase 2 medical

"interim results from the randomized, first-line Phase 2 portion of the HexAgon study"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

hexavalent medical

"INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab"

Hexavalent describes a product or substance that involves six distinct active parts or targets, commonly used for chemicals with six binding sites or vaccines that protect against six diseases. Investors should care because combining six functions into one offering can expand market reach and convenience but also raises manufacturing complexity, regulatory review and production cost — factors that affect timelines, pricing and profit potential. Think of it like a six-in-one tool versus a single-purpose tool.

ox40 agonist medical

"INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab"

An OX40 agonist is a drug that activates the OX40 protein on immune cells to strengthen the body's T‑cell response, similar to pressing a gas pedal to make immune cells work harder. Investors watch these drugs because they are a form of immunotherapy being tested to treat cancers and immune diseases; positive clinical results can greatly increase a developer's value, while failures or safety concerns can reduce it.

pembrolizumab medical

"in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy"

A cancer immunotherapy drug that helps the body’s immune system recognize and attack tumor cells by blocking a molecular “brake” that tumors use to hide. Investors watch it because regulatory approvals, clinical trial results, dosing rules, and competition directly affect potential sales, profit forecasts, and the valuation of companies that sell or license the drug—think of trial outcomes as checkpoint signs that can open or close a revenue road.

pd-l1 medical

"treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent"

PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.

head and neck squamous cell carcinoma medical

"metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)"

A type of cancer that starts in the thin, flat cells that line the mouth, throat, voice box and upper airway; imagine the lining like roof shingles that, when damaged, can grow into a harmful lump. It matters to investors because its diagnosis, treatment options and regulatory approvals drive demand for drugs, tests and therapies—affecting clinical trial outcomes, market size, company valuations and the financial risk/reward of healthcare investments.

hnscc medical

"recurrent Head and Neck Squamous Cell Carcinoma (HNSCC). Investors may join"

HNSCC stands for head and neck squamous cell carcinoma, a type of cancer that starts in the flat lining cells that cover the surfaces of the mouth, throat and related structures. It matters to investors because treatments, clinical trial results, regulatory approvals or changes in diagnosis rates can directly affect the commercial prospects and valuation of companies developing therapies or diagnostics for this disease—think of it as a market signal tied to demand for specific medical products.

webcast technical

"announced that it will host a live webcast presentation on Monday, May 11, 2026"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –

SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Monday, May 11, 2026 at 5:30 a.m. Pacific Time to provide interim results from the randomized, first-line Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

Investors may join via the web: https://app.webinar.net/0KnxG3AZlEX or may listen to the call by dialing (1-888-880-3330). Please refer to Inhibrx or the conference ID 1841482 when calling in. Following the webcast, the presentation may be accessed through a link on the "Events and Presentations" section of Inhibrx's website. The webcast will be available for 60 days following the event. Following the presentation, Inhibrx will also update its corporate presentation within the "Investors" section of its website at www.inhibrx.com.

About INBRX-106 

INBRX-106 is a hexavalent agonist targeting OX40 (CD134), a costimulatory receptor on T-cells. Utilizing Inhibrx's proprietary single-domain antibody (sdAb) platform, INBRX-106 is designed to achieve the high-order receptor clustering necessary for robust T-cell activation and survival, a feat that has eluded traditional bivalent antibody approaches.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences' current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. For more information, please visit www.inhibrx.com.

Investor and Media Contact:

Kelly Deck, CFO
ir@inhibrx.com
858-795-4260

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-inbrx-106-hexagon-study-in-first-line-hnscc-302767267.html

SOURCE Inhibrx Biosciences, Inc.

FAQ

When will Inhibrx (INBX) present interim HexAgon Phase 2 results for INBRX-106?

The webcast is scheduled for May 11, 2026 at 5:30 a.m. PT. According to Inhibrx, the live presentation will provide interim randomized Phase 2 results comparing INBRX-106 plus pembrolizumab versus pembrolizumab monotherapy in first-line PD-L1 positive HNSCC.

How can investors access the Inhibrx (INBX) HexAgon webcast on May 11, 2026?

Investors may join via the webinar link or by phone using conference ID 1841482. According to Inhibrx, the webcast URL and dial-in number are provided for live access and will be archived for 60 days after the event.

What patient population is being reported in the INBRX-106 HexAgon Phase 2 update?

The update covers first-line, treatment-naïve patients with PD-L1 positive (CPS ≥20) metastatic or unresectable recurrent HNSCC. According to Inhibrx, the randomized comparison is INBRX-106 plus pembrolizumab versus pembrolizumab alone.

Will the Inhibrx (INBX) webcast presentation be available after May 11, 2026?

Yes, the webcast will be available for 60 days following the event. According to Inhibrx, a replay link will be posted in the Events and Presentations section of the company's website for on-demand viewing.

Will Inhibrx (INBX) update its investor presentation after the HexAgon webcast?

Yes, Inhibrx will update its corporate presentation in the Investors section of its website. According to Inhibrx, the refreshed presentation will reflect the interim Phase 2 HexAgon data presented during the webcast.

What endpoints does the HexAgon study interim update on May 11, 2026 address for INBRX-106?

The announcement states the webcast will provide interim safety and efficacy results from the randomized Phase 2 portion. According to Inhibrx, the focus is on safety and efficacy of INBRX-106 plus pembrolizumab versus pembrolizumab alone in the specified patient group.